Background: Early hepatocellular carcinoma (HCC) is defined as well-differentiated HCC with an obscure tumor margin in the classification of the Liver Cancer Study Group of Japan. However, the surgical outcomes in patients with early HCC have not yet been clarified.
Methods: From 1985 to 1994, 186 patients with HCC 2 cm or less in greatest dimension underwent curative hepatectomy. Of the 186 cases, 37 were early HCC and 149 were small advanced HCC. The relationship between clinicopathological findings and surgical outcomes was examined.
Results: The rate of hepatitis C antibody or number of tumors was significantly higher in patients with early HCC than in patients with small advanced HCC. Liver function test showed no differences between patients with early HCC and patients with small advanced HCC. The 5-and 10-year survival rates were 85% and 61%, respectively, in patients with early HCC, which was significantly better than in patients with small advanced HCC (P = 0.0137). Univariate and multivariate analysis showed Child-Pugh class, intrahepatic metastasis, and early HCC to be significant prognostic factors.
Conclusions: Patients with early HCC had a different clinical background and good surgical outcomes; therefore, it should be recognized that early HCC is a distinct clinicopathological entity.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1356239 | PMC |
| http://dx.doi.org/10.1097/01.sla.0000114215.03112.e0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The correlation between contrast-enhanced ultrasound Liver Imaging Reporting and Data System classification and differentiation grades of combined hepatocellular carcinoma-cholangiocarcinoma.
Quant Imaging Med Surg
January 2025
Department of Medical Ultrasound, West China Hospital of Sichuan University, Chengdu, China.
Background: The contrast-enhanced ultrasound (CEUS) Liver Imaging Reporting and Data System (LI-RADS) classification offers a framework for risk stratification in evaluating liver lesions in patients at risk for hepatocellular carcinoma (HCC). However, its clinical utility in combined HCC-cholangiocarcinoma (cHCC-CCA) has been less extensively studied. The degree of tumor differentiation is clinically significant in determining prognosis, making the analysis of imaging features across different differentiation levels essential.
View Article and Find Full Text PDFNatural Compounds from Alhagi maurorum as Potential HCC and HepG2 Inhibitors: An Integrated Study using Pharmacophore Development, Molecular Docking, MD Simulation, and DFT Approaches.
Med Chem
January 2025
Department of Pharmacy, Pisa University, Pisa, Italy.
Background: The rise in the frequency of liver cancer all over the world makes it a prominent area of research in the discovery of new drugs or repurposing of existing drugs.
Methods: This article describes the pharmacophore-based structure-activity relationship (3DQSAR) on the secondary metabolites of Alhagi maurorum to inhibit human liver cancer cell lines Hepatocellular carcinoma (HCC) and hepatoma G2 (HepG2) which represents the molecular level understanding for isolated phytochemicals of Alhagi maurorum. The definite features, such as hydrophobic regions, average shape, and active compounds' electrostatic patterns, were mapped to screen phytochemicals.
Objectives: To determine the value of preoperative magnetic resonance imaging (MRI) in predicting macrotrabecular-massive hepatocellular carcinoma (MTM-HCC).
Materials And Methods: A search was conducted on PubMed, Web of Science, Cochrane Library databases, and Embase for studies evaluating the performance of MRI in assessing MTM-HCC. The quality assessment of diagnostic studies (QUADAS-2) tool was used to assess the risk of bias.
Survival analysis of patients with hepatocellular carcinoma based on the ratio of platelet count to spleen diameter.
Front Pharmacol
January 2025
Center for Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Background: In China, 80% of Hepatocellular Carcinoma (HCC) is associated with cirrhosis. Portal hypertension, the most common outcome of cirrhosis progression, has a high incidence. Platelet count/spleen diameter ratio (PSL) with a cut-off value of 909 can predict the presence of esophagogastric varices and thus portal hypertension, which is also an independent risk factor for early recurrence and late recurrence of hepatocellular carcinoma after resection.
View Article and Find Full Text PDFLiver transplantation for cirrhosis and its complications.
Acta Clin Belg
January 2025
Liver Research Center Ghent, Ghent University, Ghent University Hospital, Ghent, Belgium.
Objectives: To review the current indications for liver transplantation (LT) in cirrhosis, including evolving criteria for hepatocellular carcinoma (HCC) and other malignancies, how donor organ allocation is established, and to address challenges of long-term complications post-transplantation.
Methods: A comprehensive review of the literature was conducted to evaluate advancements in LT indications, pretransplant evaluation protocols, organ allocation strategies, and management approaches for long-term post-transplant complications.
Results: Liver transplantation remains the definitive treatment for cirrhosis and offers substantial survival benefits for patients with early-stage HCC.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!